Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Acute Graft Versus Host DiseaseMalignant Hematologic Neoplasm

Interventions

DRUG

Basiliximab

Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)

Trial Locations (1)

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV